New FGFR2 Inhibitor Wins FDA Approval for Cholangiocarcinoma
The FDA approved lirafugratinib for adults with previously treated cholangiocarcinoma harboring FGFR2 fusions or rearrangements. In the ReFocus trial, the drug achieved a 46% objective response rate and median progression-free survival of 11.3 months. Common severe adverse events included palmar-plantar erythrodysesthesia and stomatitis.
The approval applies specifically to patients with unresectable, locally advanced, or metastatic disease who have already received prior therapy and whose tumors carry FGFR2 fusions or rearrangements. Clinical data from 116 previously untreated-with-FGFR-inhibitors patients showed a 96.5% disease control rate, with median overall survival reaching 22.8 months and a 12-month survival rate of 74.6%.
Lirafugratinib's covalent-binding design represents a departure from earlier pan-FGFR agents, as it selectively targets FGFR2 while potentially addressing resistance mutations that arise during treatment. Safety monitoring focuses on ocular toxicity, elevated phosphate levels, soft tissue mineralization, and fetal harm risks. The manufacturer expects to make the drug available in the U.S. before the end of the year.
This approval could meaningfully alter the treatment landscape for a rare cancer where options have historically been scarce. Patients with FGFR2-positive cholangiocarcinoma may gain access to a targeted therapy offering durable responses, though the significant rates of severe side effects warrant careful patient selection and monitoring. The drug's success may also encourage broader molecular testing at diagnosis, potentially improving precision medicine approaches for other FGFR-driven malignancies.